Screener
Veradermics MANE Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The source filing: Veradermics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 5:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001827635-26-000019
| (in thousands) | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Cash flows from financing activities: | ||
| Issuance of Series B preferred stock, net of issuance costs paid | — | 8,423 |
| Initial public offering, net of issuance costs paid | 269,102 | — |
| Exercise of stock options | 11 | — |
| Net cash provided by financing activities | 269,113 | 8,423 |
| Net increase (decrease) in cash and cash equivalents | 146,646 | (20,644) |
| Cash and cash equivalents—beginning of period | 21,766 | 53,084 |
| Cash and cash equivalents—end of period | $168,412 | $32,440 |
Item 1. Condensed Consolidated Financial Statements (
FAQ
- What is Veradermics's stock issuance proceeds?
- Veradermics (MANE) reported stock issuance proceeds of $11K in Q1 2026.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.
Ask your AI about Veradermics's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude